InnoCare Pharma is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases.InnoCare has strong in-house innovation capabilities, holding multiple foreign and domestic patents with a rich product pipeline target liquid tumors, solid tumors, and autoimmune diseases. Our team has discovered and developed our current pipeline of over 11 novel drug candidates, including our core product candidate Orelabrutinib, whose NDA was accepted and granted priority review by the NMPA earlier this year. InnoCare was co-founded by Professor Shi Yigong, a world-renowned structural biologist, and Dr. Cui Jisong, an outstanding leader in the biopharmaceutical industry. We have nearly 500 employees, including over 100 researchers. Our core R&D staff brings rich experience from the world's top pharmaceutical companies, such as Pfizer, GSK, Bristol-Myers Squibb, Merck, Johnson & Johnson, Bayer, etc. We are a truly global biopharmaceutical company with sites in Beijing, Nanjing, Shanghai, and Guangzhou, in addition to branches in New Jersey and Boston for US developing and clinical management. On March 23, 2020, InnoCare officially listed on the Hong Kong Stock Exchange (code: 9969). BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL). Both new drug applications (NDAs) were previously granted priority review by the Center for Drug Evaluation (CDE) of the NMPA.Our vision is to become a world-class leader in innovative medicine and lead China's medicinal research into a new era.